Evidence-led vulnerability intelligence · 2026-10-31 12:46 IST

CVE-2026-107765

The Discussion Board – WordPress Forum Plugin plugin for WordPress is vulnerable to Stored Cross-Site Scripting in versions up to, and including, 2.6.0 via the user profile Website (user_url) field. This is due to insufficient output escaping in the ctdb_filter_comment_author_name() callback hooked to get_comment_author_link, which interpolates the raw user_url value into a single-quoted href attribute without esc_url() or esc_attr(). This makes it possible for authenticated attackers, with subscriber-level access and above, to inject arbitrary web scripts in pages that will execute whenever a user accesses a Discussion Board topic containing the attacker's reply.

MEDIUM · 6.4Web servers & CMS

Executive briefing

The source record describes: The Discussion Board – WordPress Forum Plugin plugin for WordPress is vulnerable to Stored Cross-Site Scripting in versions up to, and including, 2.6.0 via the user profile Website (user_url) field. This is due to insufficient output escaping in the ctdb_filter_comment_author_name() callback hooked to get_comment_author_link, which interpolates the raw user_url value into a single-quoted href attribute without esc_url() or esc_attr(). This makes it possible for authenticated attackers, with subscriber-level access and above, to inject arbitrary web scripts in pages that will execute whenever a user accesses a Discussion Board topic containing the attacker's reply. The practical risk depends on whether an affected product/version is present, reachable and configured in an exploitable way. Review the affected-product evidence and linked vendor advisories before assigning exposure status.

Assessment: Potential exposure only — validate the installed product, exact version, configuration and vendor applicability before treating an asset as confirmed vulnerable.

Evidence confidence: Limited Evidence-derived, not an exploitability verdict

Severity & attack characteristics

6.4 / 10 · 3.1

CVSS vector:
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:L/I:L/A:N

Attack vectorN
Attack complexityL
Privileges requiredL
User interactionN
ScopeC
Confidentiality impactL
Integrity impactL
Availability impactN

Technical explanation & impact

The technical mechanism is not expanded beyond the source description unless a referenced advisory supplies additional evidence. Read the linked vendor/CERT advisories for root-cause detail.

Potential impact must be interpreted from the published CVSS impact metrics and the affected component. A CVSS impact score is not proof that a particular asset is exploitable.

Weakness classification

CWE-79

Affected products and versions

NVD has not supplied machine-readable vulnerable CPE product/version entries for this CVE. This is an information gap, not proof that no products are affected. Check the vendor advisory references below.

Remediation & validation

  1. Identify exposure by comparing the affected product and version ranges with your asset inventory, SBOM and externally exposed services.
  2. Review the linked vendor security advisory or patch notes. Upgrade to a vendor-confirmed fixed release; do not infer a fixed version from the CVE description.
  3. Until patched, consider restricting network access or disabling the affected feature where operationally safe. These are temporary controls, not a substitute for a vendor fix.
  4. Validate the remediation with a version check and vulnerability rescan, then retain change evidence.

No fixed version is displayed unless it is explicitly established by a vendor advisory. Follow the vendor's release notes for exact product and branch applicability.

Vendor advisories, patches & exploit references

Information gaps & confidence notes

These gaps indicate missing source data. CVE Watch does not fill them with guessed product, exploit or patch details.

Last enrichment: 2026-11-03T07:50:39+00:00 · Source last modified: 2026-11-02T16:19:19.997

Open NVD record ← Back to CVE Watch

Threat intelligence, made actionable · CVE data sourced from the NVD